News
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...
Stock markets were mixed on Tuesday as investors started turning their attention from trade deals to a slew of company ...
Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Wall Street may be skeptical about Tesla’s upcoming quarters, but CEO Elon Musk made four surprising announcements that could ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback